Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Neal

Showing results (131-140 of 283) with videos related to

Pageof 29
Sort By:
BMJ Open|May 1, 2016
Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)Joanna C Thorn, Emma L Turner, Luke Hounsome, et al.
Plos One|October 3, 2015
Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on BiopsyRebecca Gilbert, Richard M Martin, David M Evans, et al.
Cancer Cell|December 25, 2012
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in manNaomi L Sharma, Charlie E Massie, Antonio Ramos-Montoya, et al.
International Journal of Cancer|March 25, 2010
Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancersShinya Hayami, John D Kelly, Hyun-Soo Cho, et al.
Molecular Cancer|March 16, 2010
Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathwayShinya Hayami, Masanori Yoshimatsu, Abhimanyu Veerakumarasivam, et al.
Journal of the National Cancer Institute|April 12, 2015
Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT studyRichard J Bryant, Daniel D Sjoberg, Andrew J Vickers, et al.
Cancer Causes & Control : CCC|March 13, 2020
Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigenSean Harrison, Kate Tilling, Emma L Turner, et al.
Neoplasia (New York, N.Y.)|July 13, 2012
RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylationHyun-Soo Cho, Shinya Hayami, Gouji Toyokawa, et al.
EMBO Molecular Medicine|February 14, 2018
Identification of potential therapeutic targets in prostate cancer through a cross-species approachSarah Jurmeister, Antonio Ramos-Montoya, Chiranjeevi Sandi, et al.
BJU International|July 15, 2016
Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of lifeAthene Lane, Chris Metcalfe, Grace J Young, et al.
Pageof 29

Showing results (131-140 of 283) with videos related to

Sort By:
Pageof 29
BMJ Open|May 1, 2016
Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)Joanna C Thorn, Emma L Turner, Luke Hounsome, et al.
Plos One|October 3, 2015
Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on BiopsyRebecca Gilbert, Richard M Martin, David M Evans, et al.
Cancer Cell|December 25, 2012
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in manNaomi L Sharma, Charlie E Massie, Antonio Ramos-Montoya, et al.
International Journal of Cancer|March 25, 2010
Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancersShinya Hayami, John D Kelly, Hyun-Soo Cho, et al.
Molecular Cancer|March 16, 2010
Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathwayShinya Hayami, Masanori Yoshimatsu, Abhimanyu Veerakumarasivam, et al.
Journal of the National Cancer Institute|April 12, 2015
Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT studyRichard J Bryant, Daniel D Sjoberg, Andrew J Vickers, et al.
Cancer Causes & Control : CCC|March 13, 2020
Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigenSean Harrison, Kate Tilling, Emma L Turner, et al.
Neoplasia (New York, N.Y.)|July 13, 2012
RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylationHyun-Soo Cho, Shinya Hayami, Gouji Toyokawa, et al.
EMBO Molecular Medicine|February 14, 2018
Identification of potential therapeutic targets in prostate cancer through a cross-species approachSarah Jurmeister, Antonio Ramos-Montoya, Chiranjeevi Sandi, et al.
BJU International|July 15, 2016
Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of lifeAthene Lane, Chris Metcalfe, Grace J Young, et al.
Pageof 29